BHC and BLCO Related Headlines
Go Back- Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
- Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
- Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
- BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
- Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
- Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
- Bausch Health Announces 2026 Gastrointestinal Health Scholars Program
- Bausch Health phase 3 trials for liver cirrhosis treatment fail primary endpoint
- Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
- Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
- Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
- Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
- Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
- Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Bausch + Lomb Announces Two Board of Directors Appointments
- Bausch + Lomb plans $2.8 billion loan refinancing to cut interest rates
- Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
- Bausch + Lomb to Participate in Citi Global Healthcare Conference
- Bausch + Lomb sets three-year growth targets at investor day
- Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
- Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program
- Bausch + Lomb to Hold Investor Day on Nov. 13
- Bausch + Lomb Announces Third-Quarter 2025 Results
- Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13
- Bausch Health completes DURECT acquisition for $63 million
- Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
- Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
- Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
- Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States
- Bausch + Lomb board members resign after Icahn agreement ends
- Bausch + Lomb Announces Board Changes
- Bausch + Lomb to Participate in Upcoming Investor Conferences
BHC and BLCO Related Press Releases
Go Back- Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
- Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
- Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
- BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
- Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
- Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
- Bausch Health Announces 2026 Gastrointestinal Health Scholars Program
- Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
- Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
- Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
- Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
- Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
- Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Bausch + Lomb Announces Two Board of Directors Appointments
- Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
- Bausch + Lomb to Participate in Citi Global Healthcare Conference
- Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
- Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program
- Bausch + Lomb to Hold Investor Day on Nov. 13
- Bausch + Lomb Announces Third-Quarter 2025 Results
- Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13
- Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
- Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
- Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
- Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States
- Bausch + Lomb Announces Board Changes
- Bausch + Lomb to Participate in Upcoming Investor Conferences
BHC and BLCO Related SEC Filings
Go Back- Form 4 Bausch & Lomb Corp For: Mar 03 Filed by: Ross Thomas W. Sr.
- Form 4 Bausch & Lomb Corp For: Feb 27 Filed by: VON ESCHENBACH ANDREW C.
- Form 4 Bausch & Lomb Corp For: Mar 02 Filed by: Alfonso Eduardo
- Form 4 Bausch & Lomb Corp For: Feb 26 Filed by: Munsch Frederick
- Form 4 Bausch & Lomb Corp For: Feb 26 Filed by: Stewart Andrew J.
- Form 4 Bausch & Lomb Corp For: Feb 26 Filed by: Bonnefoy Luc
- Form 4 Bausch & Lomb Corp For: Feb 26 Filed by: Hashad Yehia
- Form 4 Bausch & Lomb Corp For: Feb 26 Filed by: Bailey A Robert D
- Form 4 Bausch & Lomb Corp For: Feb 26 Filed by: Eldessouky Sam
- Form 4 Bausch & Lomb Corp For: Feb 26 Filed by: SAUNDERS BRENT L
- Form 4 Bausch & Lomb Corp For: Feb 25 Filed by: Bonnefoy Luc
- Form 4 Bausch & Lomb Corp For: Feb 25 Filed by: Munsch Frederick
- Form 4 Bausch & Lomb Corp For: Feb 25 Filed by: Stewart Andrew J.
- Form 4 Bausch & Lomb Corp For: Feb 25 Filed by: Hashad Yehia
- Form 4 Bausch & Lomb Corp For: Feb 25 Filed by: Bailey A Robert D
- Form 4 Bausch & Lomb Corp For: Feb 25 Filed by: Eldessouky Sam
- Form 4 Bausch & Lomb Corp For: Feb 25 Filed by: SAUNDERS BRENT L
- Form 4 Bausch & Lomb Corp For: Feb 23 Filed by: SAUNDERS BRENT L
- Form 4 Bausch & Lomb Corp For: Feb 23 Filed by: COLLIS STEVEN H
- Form 4 Bausch & Lomb Corp For: Feb 20 Filed by: ROBERTSON RUSSEL C
- Form 4 Bausch & Lomb Corp For: Feb 19 Filed by: Ling Karen
- Form 4 Bausch & Lomb Corp For: Feb 19 Filed by: COLLIS STEVEN H
- Form 4 Bausch & Lomb Corp For: Feb 19 Filed by: Alfonso Eduardo
- Form 4 Bausch & Lomb Corp For: Feb 19 Filed by: ROBERTSON RUSSEL C
- Form 4 Bausch & Lomb Corp For: Feb 19 Filed by: Paulson John
- Form 4 Bausch & Lomb Corp For: Feb 18 Filed by: Munsch Frederick
- Form 4 Bausch & Lomb Corp For: Feb 18 Filed by: Bonnefoy Luc
- Form 4 Bausch & Lomb Corp For: Feb 18 Filed by: Hashad Yehia
- Form 4 Bausch & Lomb Corp For: Feb 18 Filed by: Eldessouky Sam
- Form 10-K Bausch & Lomb Corp For: Dec 31
- Form 8-K Bausch & Lomb Corp For: Feb 18
- Form 3 Bausch & Lomb Corp For: Jan 01 Filed by: COLLIS STEVEN H
- Form 3 Bausch & Lomb Corp For: Jan 01 Filed by: Alfonso Eduardo
- Form 8-K Bausch & Lomb Corp For: Jan 02
- Form 8-K/A Bausch & Lomb Corp For: Dec 17
- Form 8-K Bausch & Lomb Corp For: Dec 17
- Form 8-K Bausch & Lomb Corp For: Dec 12
- Form 4 Bausch & Lomb Corp For: Nov 14 Filed by: ROBERTSON RUSSEL C
- Form 4 Bausch & Lomb Corp For: Nov 14 Filed by: Paulson John
- Form 8-K Bausch & Lomb Corp For: Nov 13
- Form 10-Q Bausch & Lomb Corp For: Sep 30
- Form 8-K Bausch & Lomb Corp For: Oct 29
- Form 8-K Bausch & Lomb Corp For: Aug 14
